{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T20:29:10Z","timestamp":1769200150846,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.clml.2024.09.007","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T13:53:45Z","timestamp":1727099625000},"page":"e110-e119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real World Outcome of High-Risk Multiple Myeloma: An Indian Tertiary Care Centre Experience"],"prefix":"10.1016","volume":"25","author":[{"given":"Anveshika","family":"Soni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3040-5968","authenticated-orcid":false,"given":"Sujay","family":"Rainchwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reema","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9449-7585","authenticated-orcid":false,"given":"Dikshat Gopal","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6946-5336","authenticated-orcid":false,"given":"Nakul","family":"Tikare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohan","family":"Halder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy J.","family":"Palatty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vipul Sharad","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8743-1801","authenticated-orcid":false,"given":"Narendra","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh","family":"Bhurani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9009-1302","authenticated-orcid":false,"given":"Tribikram","family":"Panda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.clml.2024.09.007_bib0001","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1172\/JCI61188","article-title":"Molecular pathogenesis of multiple myeloma and its premalignant precursor","volume":"122","author":"Kuehl","year":"2012","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.clml.2024.09.007_bib0002","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3390\/cancers13030396","article-title":"Metabolic effects of recurrent genetic aberrations in multiple myeloma","volume":"13","author":"Bloedjes","year":"2021","journal-title":"Cancers"},{"issue":"26","key":"10.1016\/j.clml.2024.09.007_bib0003","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.09.007_bib0004","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/jha2.675","article-title":"Variability of definition of high-risk multiple myeloma across phase III clinical trials","volume":"4","author":"Abu Za'nouneh","year":"2023","journal-title":"EJHaem"},{"issue":"5","key":"10.1016\/j.clml.2024.09.007_bib0005","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2024.09.007_bib0006","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/S2352-3026(20)30361-6","article-title":"High-risk myeloma: a challenge to define and to determine the optimal treatment","volume":"8","author":"Pawlyn","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2024.09.007_bib0007","series-title":"Risk stratification and targets in multiple myeloma: from genomics to the bedside","first-page":"675","volume":"38","author":"Perrot","year":"2018"},{"issue":"8","key":"10.1016\/j.clml.2024.09.007_bib0008","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/ajh.27327","article-title":"High-risk multiple myeloma: redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapy","volume":"99","author":"Rees","year":"2024","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.clml.2024.09.007_bib0009","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.09.007_bib0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5858\/arpa.2010-0645-SA","article-title":"Cytogenetics Resource Committee of the College of American Pathologists. Validation of fluorescence in situ hybridization using an analyte-specific reagent for detection of abnormalities involving the mixed lineage leukemia gene","volume":"136","author":"Saxe","year":"2012","journal-title":"Arch Pathol Lab Med"},{"issue":"11","key":"10.1016\/j.clml.2024.09.007_bib0011","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1182\/blood.2022017863","article-title":"Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del (1p32) remains a strong prognostic factor","volume":"141","author":"Schavgoulidze","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.09.007_bib0012","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/leu.2013.225","article-title":"Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients","volume":"28","author":"Hebraud","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.clml.2024.09.007_bib0013","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.bbmt.2007.05.014","article-title":"Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant","volume":"13","author":"Qazilbash","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.clml.2024.09.007_bib0014","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41408-021-00432-4","article-title":"Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life","volume":"11","author":"Terpos","year":"2021","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.clml.2024.09.007_bib0015","doi-asserted-by":"crossref","first-page":"e685","DOI":"10.1016\/j.clml.2022.03.005","article-title":"Presentation and impact of double and triple hit cytogenetics in patients with multiple myeloma in the real world","volume":"22","author":"Singh","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"10.1016\/j.clml.2024.09.007_bib0016","doi-asserted-by":"crossref","first-page":"e685","DOI":"10.1016\/j.clml.2022.03.005","article-title":"Presentation and impact of double and triple hit cytogenetics in patients with multiple myeloma in the real world","volume":"22","author":"Singh","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"10.1016\/j.clml.2024.09.007_bib0017","first-page":"918","article-title":"Clinical prognosis analysis of patients with\" double hit\" multiple myeloma","volume":"40","author":"Luo","year":"2019","journal-title":"Zhonghua xue ye xue za zhi= Zhonghua Xueyexue Zazhi"},{"issue":"11","key":"10.1016\/j.clml.2024.09.007_bib0018","first-page":"912","article-title":"Adverse effects of double-hit combining ISS-\u2162 stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma","volume":"40","author":"Liu","year":"2019","journal-title":"Zhonghua xue ye xue za zhi= Zhonghua Xueyexue Zazhi"},{"issue":"1","key":"10.1016\/j.clml.2024.09.007_bib0019","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s12185-022-03332-w","article-title":"Korean Multiple Myeloma Working Party (KMMWP). Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805)","volume":"116","author":"Kim","year":"2022","journal-title":"Int J Hematol"},{"issue":"2","key":"10.1016\/j.clml.2024.09.007_bib0020","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2024.09.007_bib0021","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3390\/cancers15030962","article-title":"Attrition rates in multiple myeloma treatment under real world conditions\u2014an analysis from the Austrian Myeloma Registry (AMR)","volume":"15","author":"Benda","year":"2023","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.clml.2024.09.007_bib0022","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jtct.2023.08.028","article-title":"Overcoming barriers to autologous stem cell transplantation in multiple myeloma: recommendations from a multidisciplinary roundtable discussion","volume":"29","author":"Bashir","year":"2023","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.clml.2024.09.007_bib0023","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1182\/blood-2023-182051","article-title":"Exploring autologous hematopoietic stem cell transplantation (HSCT) Utilization and HSCT refusal trends in multiple myeloma patients: a comprehensive examination of NCDB data from 2004 to 2020","volume":"142","author":"Chaulagain","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2024.09.007_bib0024","doi-asserted-by":"crossref","first-page":"e826","DOI":"10.1016\/j.clml.2022.04.020","article-title":"Multiple myeloma: impact of time to transplant on the outcome","volume":"22","author":"Kumar","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.clml.2024.09.007_bib0025","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jtct.2023.08.031","article-title":"Outcomes of autologous stem cell transplantation in patients with ultra-high-risk multiple myeloma","volume":"29","author":"Pasvolsky","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.clml.2024.09.007_bib0026","doi-asserted-by":"crossref","first-page":"e831","DOI":"10.1097\/HS9.0000000000000831","article-title":"Impact of ultra high-risk genetics on real-world outcomes of transplant-eligible multiple myeloma patients","volume":"7","author":"Panopoulou","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2024.09.007_bib0027","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/S2152-2650(21)02288-6","article-title":"P-161: Ultra-high-risk prognostic significance of double and triple hit myeloma","volume":"21","author":"Bila","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.clml.2024.09.007_bib0028","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41409-024-02200-x","article-title":"The impact of social vulnerability index on survival following autologous stem cell transplant for multiple myeloma","volume":"59","author":"Salafian","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2024.09.007_bib0029","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1182\/blood-2023-180637","article-title":"Income and education affect prognosis and treatment in symptomatic myeloma: a population-based study on 8672 multiple myeloma patients diagnosed 2008-2021 from the Swedish myeloma registry","volume":"142","author":"Larfors","year":"2023","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024023516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024023516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T10:59:29Z","timestamp":1738061969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024023516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2152265024023516"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.09.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real World Outcome of High-Risk Multiple Myeloma: An Indian Tertiary Care Centre Experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}